Hancock Whitney Corp Sells 74 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hancock Whitney Corp lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,805 shares of the biopharmaceutical company’s stock after selling 74 shares during the period. Hancock Whitney Corp’s holdings in Regeneron Pharmaceuticals were worth $8,203,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. West Paces Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares in the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $26,000. Sachetta LLC increased its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold 10,026 shares of company stock worth $11,498,705 over the last three months. Insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on REGN shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $1,282.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of NASDAQ:REGN opened at $1,145.03 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a market capitalization of $126.17 billion, a P/E ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. The company has a 50-day simple moving average of $1,131.75 and a 200 day simple moving average of $1,031.74. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $8.79 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.